Literature DB >> 12851770

[Overactive bladder--treatment with antimuscarinic agents].

K Höfner1.   

Abstract

Today, urgency and urge incontinence are both defined under the topic overactive bladder (OAB) whereby pure urge syndrome (pollakisuria, nocturia, and urgency) can easily lead to urge incontinence. Antimuscarinics still constitute the domain of treatment for overactive bladder. The pharmacological effect of modern substances consists of M2 or M3 muscarinic receptor blockade. This blockade prevents acetylcholine from connecting to these receptors and thus leads to a weakness or prevention of the detrusor muscle contraction. These groups of drugs are defined as muscarinic receptor antagonists, antimuscarinics, or anticholinergics. In addition to the muscarinic receptors, some drugs directly block the calcium channels in the cell membrane (calcium antagonists) which are classified as drugs with mixed effect. The presented paper gives an overview about the existing data on drugs approved in Germany whose clinical effect has been proven in randomized studies or are have stood the test of time in daily clinical practice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12851770     DOI: 10.1007/s00120-003-0363-y

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  51 in total

1.  The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study.

Authors:  A J Tapp; L D Cardozo; E Versi; D Cooper
Journal:  Br J Obstet Gynaecol       Date:  1990-06

2.  A comparison of emepronium bromide and flavoxate hydrochloride in the treatment of urinary incontinence.

Authors:  S L Stanton
Journal:  J Urol       Date:  1973-11       Impact factor: 7.450

3.  Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomised trial.

Authors:  H Enzelsberger; H Helmer; C Kurz
Journal:  Br J Obstet Gynaecol       Date:  1995-11

4.  Treatment of motor urge incontinence with clenbuterol and flavoxate hydrochloride.

Authors:  A Grüneberger
Journal:  Br J Obstet Gynaecol       Date:  1984-03

5.  Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo.

Authors:  J W Thüroff; B Bunke; A Ebner; P Faber; P de Geeter; J Hannappel; H Heidler; H Madersbacher; H Melchior; W Schäfer
Journal:  J Urol       Date:  1991-04       Impact factor: 7.450

6.  Topical oxybutynin chloride for relaxation of dysfunctional bladders.

Authors:  C B Brendler; L C Radebaugh; J L Mohler
Journal:  J Urol       Date:  1989-06       Impact factor: 7.450

7.  Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder.

Authors:  R Kaplinsky; S Greenfield; J Wan; M Fera
Journal:  J Urol       Date:  1996-08       Impact factor: 7.450

8.  Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder.

Authors:  M Mizunaga; M Miyata; S Kaneko; S Yachiku; K Chiba
Journal:  Paraplegia       Date:  1994-01

9.  Inhibitory effects of propiverine hydrochloride on the agonist-induced or spontaneous contractions of various isolated muscle preparations.

Authors:  A Haruno
Journal:  Arzneimittelforschung       Date:  1992-06

10.  Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.

Authors:  P Abrams; R Freeman; C Anderström; A Mattiasson
Journal:  Br J Urol       Date:  1998-06
View more
  3 in total

Review 1.  [Dynamic bladder neck stenosis as a cause of psychogenic mictrition discomforts and mictrition disorders].

Authors:  E-A Günthert
Journal:  Urologe A       Date:  2004-05       Impact factor: 0.639

Review 2.  [Medical combination therapy in LUTS suggestive of BPH].

Authors:  K Höfner; M Oelke
Journal:  Urologe A       Date:  2009-03       Impact factor: 0.639

Review 3.  [Medical therapy of urinary incontinence].

Authors:  M Oelke; J J de la Rosette; M C Michel; U Jonas
Journal:  Internist (Berl)       Date:  2005-01       Impact factor: 0.743

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.